Search

Displaying results 7441 - 7450 of 10000 in total
  1. Drug

    Lixudebart

    go.drugbank.com/drugs/DB19244
    Investigational

    Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]

  2. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  3. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  4. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Mizacorat is a glucocorticoid receptor agonist. … Mizacorat has a monoisotopic molecular weight of 494.21 Da.

  5. Drug

    JNJ-54175446

    go.drugbank.com/drugs/DB15358
    Investigational

    JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid

  6. Drug

    Hydrocortisone phosphate

    go.drugbank.com/drugs/DB14542
    ApprovedInvestigationalVet approved

  7. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

  8. Drug

    Chlorophyll A

    go.drugbank.com/drugs/DB02133
    Experimental

    Synonyms: Chlorophyll ACategories: Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Segatroxaban

    go.drugbank.com/drugs/DB21678
    Experimental

    Segatroxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Segatroxaban is a blood coagulation factor XA​ inhibitor, antithrombotic. … Segatroxaban has a monoisotopic molecular weight of 567.14 Da.

  10. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).